Unlearn
CA - San FranciscoBiotechnology
Focus: Unlearn develops machine-learning technology that creates digital twins of patients to optimize clinical trial design and execution, positioning itself as an emerging AI-driven platform company in the clinical trials space. The company operates at the intersection of biotechnology and health tech, targeting efficiency gains in drug development.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Open Jobs
5-2 this month
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Should You Work at Unlearn?
AI assessmentStrong fit for technologists and data scientists seeking early-stage AI impact in clinical trials; higher risk for those prioritizing financial transparency and predictable career progression.
Why Work Here
- Join a recognized AI/clinical trials innovator — Unlearn ranked in top 10 AI clinical trial companies in 2026 and collaborating with pharma like Acumen Pharmaceuticals on Alzheimer's programs
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Unlearn
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.